Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

Exclusion criteria

• . Previous use of any CAR T cell products or other genetically modified T cell therapy;
• . Patients who have a history of allogeneic stem cells or solid organ transplantation or are waiting for organ transplantation;
• . Patients with acute or uncontrolled active infection who currently require intravenous anti-infective therapy, and patients taking antibiotics to prevent infection should be allowed to participate in the study at the discretion of the investigator;
• . Active hepatitis B (hepatitis B surface antigen positive and hepatitis B DNA\>103 copies /mL or \>200IU/mL), active hepatitis C (hepatitis C antibody positive and RNA positive); Active syphilis infection (RPR or TRUst-positive), human immunodeficiency virus (HIV) infection (HIV positive);
• . Patients with low sodium and/or hypokalemia with blood sodium \<125mmol/L and/or blood potassium \<3.5mmol/L (unless sodium and/or potassium supplementation is required prior to study participation to restore blood sodium and/or potassium above this level);
• . Imaging results showed that the proportion of liver replaced by tumor was ≥50%;
• . There was clinically uncontrollable third space effusion, which was judged by the researcher not suitable for inclusion;
• . Previously received anti-CD70 therapy;